Table 2.
Baseline characteristics of the lowest and highest HbA1c group
| Baseline characterization | Lowest | Highest | Total number | |
|---|---|---|---|---|
| Lowest | Highest | |||
| Male (%), studies = 19 | 71.69% | 73.45% | 45,354 | 10,909 |
| Age (year), studies = 19 | 61.25602 | 62.03319 | 45,354 | 10,909 |
| Smoker (%), studies = 15 | 42.25% | 39.54% | 43,277 | 9681 |
| BMI (kg/m2), studies = 11 | 25.87935 | 26.00163 | 283 | 301 |
| BMI > 30 kg/m2 (%), studies = 2 | 21.15% | 22.22% | 52 | 63 |
| Previous MI (%), studies = 11 | 16.73% | 15.57% | 39,307 | 8737 |
| Hypertension (%), studies = 15 | 38.52% | 43.27% | 9157 | 4708 |
| Heart failure (%), studies = 3 | 5.24% | 5.79% | 36,565 | 6925 |
| Cerebrovascular accident (%), studies = 6 | 4.96% | 5.58% | 37,262 | 7281 |
| Hyperlipidemia (%), studies = 10 | 47.72% | 41.92% | 41,808 | 7855 |
| Renal insufficiency (%), studies = 3 | 26.47% | 25.35% | 774 | 447 |
| Antiplatelet (%), studies = 2 | 17.47% | 20.54% | 596 | 294 |
| Aspirin (%), studies = 2 | 34.50% | 33.60% | 35,325 | 5952 |
| Clopidogrel (%), studies = 2 | 7.69% | 8.35% | 35,325 | 5952 |
| PCI (%), studies = 6 | 8.42% | 10.78% | 3031 | 2283 |
| CABG (%), studies = 4 | 2.43% | 4.08% | 1745 | 1323 |
| ACEI/ARB (%), studies = 4 | 27.97% | 34.02% | 36,013 | 6276 |
| Lipid lowering drugs (%), studies = 4 | 27.76% | 25.24% | 36,013 | 6276 |
| Beta-blocker (%), studies = 3 | 26.39% | 27.11% | 35,901 | 6194 |
| Creatinine (mg/dl), studies = 4 | 1.259,418 | 1.105723 | 1388 | 1839 |
| eGFR (mg/dl/1.73 m2), studies = 5 | 87.00478 | 68.16183 | 5507 | 1654 |
| Admission plasma glucose, studies = 11 | 7.84536 | 9.461979 | 4831 | 4171 |
| Killip ≥ 3 (%), studies = 3 | 11.75% | 14.33% | 1081 | 1584 |
| Killip ≥ 2 (%), studies = 8 | 9.88% | 16.68% | 5782 | 1915 |
BMI body mass index, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, eGFR estimated glomerular filtration rate